Experimental CAR-T injection aims to tame autoimmune diseases
NCT ID NCT07613411
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests an injection called KSVCBD, a type of CAR-T cell therapy, in 60 adults with severe autoimmune diseases like lupus and scleroderma. The goal is to see if it's safe and to get a first look at whether it might help control the disease. Participants receive a single IV infusion and are monitored for side effects and response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KSVCBD injection (a type of CAR-T cell therapy given by IV infusion)
What this could lead to
If successful, this could point toward a new treatment option for people with severe autoimmune diseases that haven't responded to other therapies.
What could go wrong
This is a very early, small trial (60 people) focused on safety, so it's too soon to know if it works. There are risks like severe immune reactions and infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853, China
Contact Phone: •••-•••-•••• Email: •••••@•••••